home · filing · 0001193125-21-284964
8-K filed September 28, 2021, 7:59 PM ET
ticker ALEC
CIK 0001653087
leadership
confidence high
sentiment neutral
materiality 0.30
Alector appoints Elizabeth Garofalo, M.D. to Board of Directors
Alector, Inc.
Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.
Over 25 years of neurology drug development experience; formerly SVP and Global Head of Clinical Development at Novartis.
Received initial option grant of 33,235 shares (four-year vest) and annual cash retainer of $40,000.
Currently serves on boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Elizabeth A. Garofalo
Class II director
Effective 2021-09-23
Filed September 28, 2021, 7:59 PM ET
On September 23, 2021, Elizabeth A. Garofalo, M.D. was appointed to the Board of Directors (the “Board”) of Alector, Inc. (the “Company”).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elizabeth A. Garofalo was appointed as Class II director at Alector, Inc..
Action appointed
Role Class II director
Exact text from the filing
On September 23, 2021, Elizabeth A. Garofalo, M.D. was appointed to the Board of Directors (the “Board”) of Alector, Inc. (the “Company”).
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-284964
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.